论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, Wei Y, He G, Xu J
Received 22 April 2018
Accepted for publication 28 June 2018
Published 17 September 2018 Volume 2018:10 Pages 3569—3577
DOI https://doi.org/10.2147/CMAR.S171855
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Justinn Cochran
Peer reviewer comments 2
Editor who approved publication: Dr Antonella D'Anneo
Purpose: Tumor purity is defined as the proportion of cancer cells in the
tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis,
genetic profile, and microenvironment has not been thoroughly accessed.
Materials and
methods: Clinical and transcriptomic data
from three public datasets, GSE17536/17537, GSE39582, and TCGA, were
retrospectively collected (n=1,248). Tumor purity of each sample was inferred
by a computational method based on transcriptomic data. Survival-related
analyses were performed on microarray dataset containing GSE17536/17537 and
GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic
analysis (n=454).
Results: Right-sided CC patients showed a significantly lower tumor purity.
Low purity CC conferred worse survival, and tumor purity was identified as an
independent prognostic factor. Moreover, high tumor purity CC patients
benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that
the mutation burden was negatively associated with tumor purity, with
only APC and KRAS significantly more mutated in
high purity CC. However, no somatic copy number alteration event was correlated
with tumor purity. Furthermore, immune-related pathways and
immunotherapy-associated markers (programmed cell death protein 1 [PD-1],
programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4
[CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and
mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples.
Notably, the relative proportion of M2 macrophages and neutrophils, which
indicated worse survival in CC, was negatively associated with tumor purity.
Conclusion: Tumor purity exhibited potential value for CC prognostic
stratification as well as adjuvant chemotherapy benefit prediction. The
relative worse survival in low purity CC may attribute to higher mutation
frequency in key pathways and purity-related microenvironmental changing.
Keywords: adjuvant chemotherapy, colon cancer, prognosis, tumor
microenvironment, tumor purity